Who owns RLAY? 13F holders and whale ownership
RLAY is tracked across public portfolios in Whale Analyzer. This page answers who owns RLAY, which top funds are buying RLAY, aggregate disclosed value, and recent position changes based on public data. Joseph Edelman is the largest reported holder at $97M; the top five funds control 100.0% of reported ownership; institutions were net buying last quarter (1 increased, 0 reduced); the stock trades above the aggregate whale cost basis of $10.56. Top tracked holders include Joseph Edelman and Baker Bros. Advisors.
Continue to the live RLAY dashboardTop holders
| Investor | Reported value | Shares | Change |
|---|---|---|---|
| Joseph Edelman 13F portfolio Perceptive Advisors holdings | $97.0M | 9.8M | Increased |
| Baker Bros. Advisors 13F portfolio Baker Bros. Advisors holdings | $11.5M | 1.2M | Held |
Ownership concentration
Reported ownership of RLAY is highly concentrated across tracked institutions.
- Single largest holder: 89.4% of reported ownership
- Top 5 holders: 100.0%
- Top 10 holders: 100.0%
Whale activity this quarter
Across 2 tracked institutions, 1 increased, 1 held. Net positioning is net buying.
- Joseph Edelman — Perceptive Advisors ($97.0M) (▲ 412.3% qoq shares) · avg cost $10.44
- Baker Bros. Advisors — Baker Bros. Advisors ($11.5M) (→ 0.0% qoq shares) · avg cost $11.49
Whale cost basis vs current price
The aggregate tracked cost basis is $10.56 versus a current price of $18.56, so RLAY trades above its cost basis (+75.8%). Average unrealized P&L across tracked holders: 19%.
Sector positioning — Health Care
RLAY sits within the Health Care sector alongside 221 other tracked names. Compare whale ownership across peers:
How to use this page
Values are reported public positions from tracked 13F filers and disclosures — not real-time ownership totals. Open the live RLAY dashboard for price charts and cross-investor scans, or read the SEC 13F guide.
Related stock holder pages
- PRAX whale holders — PRAXIS PRECISION MEDICINES I
- CELC whale holders — CELCUITY INC
- ASND whale holders — ASCENDIS PHARMA A/S
- ROIV whale holders — ROIVANT SCIENCES LTD
- CNTA whale holders — CENTESSA PHARMACEUTICALS PLC
- RYTM whale holders — RHYTHM PHARMACEUTICALS INC
- SYRE whale holders — SPYRE THERAPEUTICS INC
- NUVL whale holders — NUVALENT INC
Learn more in Whale Analyzer Academy
Deepen your read on RLAY with these Whale Analyzer Academy guides:
Frequently asked questions
Who owns RLAY stock?
Whale Analyzer tracks 2 public institutional holders of RLAY with a combined reported value of $108.6M. See the holder table above for the largest tracked positions.
Which top funds are buying RLAY?
Tracked institutions were net buying last quarter — 1 increased, 1 held. Check the "Change" column: "New" = fresh position, "Increased" = added, "Reduced" = trimmed.
How concentrated is RLAY ownership?
The top five tracked holders report 100.0% of aggregate ownership.
Is RLAY above or below the whale cost basis?
The aggregate tracked cost basis is $10.56 versus a current price of $18.56 (+75.8%).
What does 13F ownership mean for RLAY?
Use the interactive RLAY dashboard on Whale Analyzer for real-time holder analysis, or read our 13F Alpha Signals Guide.